Baltimore-based Profectus BioSciences in the coming months will begin a human clinical trial for its Ebola vaccine after a successful animal study.

Profectus’ VesiculoVax prevented monkeys from contracting and dying of Ebola Makona, the strain of the virus that led to the current Ebola outbreak in West Africa. The study’s findings will on Thursday be published in the journal Nature. Profectus expects to begin human trials in June.

The animal study and the human clinical trials ahead are key steps to making the vaccine available in West Africa, where an outbreak of the virus has killed 10,000 people.

Read more via the Baltimore Business Journal.